이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ZimVie 배당금

배당금 기준 확인 0/6

ZimVie 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$1.87
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

ZimVie: Guidance Suggests Company Fairly Valued At The Moment (Rating Downgrade)

Jun 04

ZimVie: Shrinking Its Way To Profitability

Feb 12

ZimVie Inc. (NASDAQ:ZIMV) Stock Catapults 93% Though Its Price And Business Still Lag The Industry

Dec 19

ZimVie Inc.'s (NASDAQ:ZIMV) Shares Bounce 27% But Its Business Still Trails The Industry

Apr 17

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 ZIMV 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: ZIMV 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

ZimVie 시장 대비 배당 수익률

ZIMV 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (ZIMV)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.8%
업계 평균 (Medical Equipment)	1.8%
3년 후 애널리스트 예측 (ZIMV)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ZIMV 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ZIMV 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ZIMV 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: ZIMV 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

ZimVie 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Now 65% undervalued

Now 64% undervalued

Now 64% undervalued

Now 32% overvalued after recent price rise

Now 31% overvalued after recent price rise

Now 42% overvalued after recent price rise

Now 21% overvalued

ZimVie: Guidance Suggests Company Fairly Valued At The Moment (Rating Downgrade)

President exercised options and sold US$356k worth of stock

ZimVie Inc. Provides Earnings Guidance for the Full Year 2024 Ending December 31, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ZimVie Inc. to Report Q1, 2024 Results on May 08, 2024

President exercised options and sold US$172k worth of stock

H.I.G. Capital, LLC completed the acquisition of Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV).

ZimVie Inc., Annual General Meeting, May 15, 2024

ZimVie Inc., Annual General Meeting, May 15, 2024

President exercised options and sold US$163k worth of stock

Price target increased by 19% to US$16.00

New minor risk - Shareholder dilution

ZimVie Inc. Provides Earnings Guidance for First Quarter and Raises Earnings Guidance for the Full Year 2024

Full year 2023 earnings: EPS misses analyst expectations

ZimVie Inc. to Report Q4, 2023 Results on Feb 28, 2024

ZimVie: Shrinking Its Way To Profitability

ZimVie Inc. Announces Launch of Next-Generation TSX®? Implant in Japan

H.I.G. Capital, LLC entered into an Equity Purchase Agreement to acquire Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV) for approximately $380 million.

ZimVie Inc. (NASDAQ:ZIMV) Stock Catapults 93% Though Its Price And Business Still Lag The Industry

H.I.G. Capital, LLC entered into an Equity Purchase Agreement to acquire Zimmer Biomet Spine, Inc. from ZimVie Inc. (NasdaqGS:ZIMV) for approximately $380 million.

ZimVie Inc. Announces Compatibility Between Its Vital Spinal Fixation System and Brainlab Spine & Trauma Navigation

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.032 profit in 3Q 2022)

Zimvie Inc. Revises Earnings Guidance for the Full Year Ending December 31, 2023

ZimVie Inc. Announces First U.S. Surgery with the 4.5mm Mobi-C(R) Cervical Disc

ZimVie Inc. Announces the Launch of Azure Multi-Platform Product Solutions

ZimVie Inc. to Report Q3, 2023 Results on Nov 01, 2023

ZimVie Inc. Announces the Recent Launch of Biotivity A/C Plus Membrane

ZimVie Announces FDA Approval to Launch Mobi-C® Hybrid Study

ZimVie Inc. Announces FDA Approval for New Mobi-C(R) Implant

Second quarter 2023 earnings released: US$0.89 loss per share (vs US$0.33 loss in 2Q 2022)

ZimVie Inc. Revises Financial Guidance for the Full Year Ending December 31, 2023

New minor risk - Share price stability

ZimVie Inc. to Report Q2, 2023 Results on Aug 02, 2023

First quarter 2023 earnings released: US$1.14 loss per share (vs US$0.98 loss in 1Q 2022)

Zimvie Inc. Revises Earnings Guidance for the Full Year 2023

ZimVie Inc.'s (NASDAQ:ZIMV) Shares Bounce 27% But Its Business Still Trails The Industry

President recently bought US$122k worth of stock

Full year 2022 earnings released: US$2.45 loss per share (vs US$3.66 loss in FY 2021)

ZimVie Inc. to Report Q4, 2022 Results on Mar 01, 2023

ZimVie Inc. Announces Over 200,000 Cervical Discs Have Been Replaced with Mobi-C

High number of new and inexperienced directors

ZimVie Inc. Reaffirms Revenue Guidance for the Year 2022

Zimvie Announces Launch of Next-Generation TSX™ Implant in the United States

ZimVie Inc. to Report Q3, 2022 Results on Nov 09, 2022

Zimvie Expands Navigation-Compatible Platform to Include Posterior Cervical Application

ZimVie Inc.(NasdaqGS:ZIMV) dropped from FTSE All-World Index (USD)

ZimVie: Disappointing Guidance Prompts Caution

Second quarter 2022 earnings released

ZimVie Inc. Revises Net Sales Guidance for the Year 2021

ZimVie Q2 Non-GAAP EPS beats, revenue down Y/Y, guidance reduced

ZimVie Inc. to Report Q2, 2022 Results on Aug 10, 2022

ZimVie: Undervalued Spin-Off

Zimvie Inc. Announces Launch of Two Next-Generation Dental Solutions in the United States

Executive VP recently bought US$205k worth of stock

High number of new and inexperienced directors

ZimVie: Spin-Off Of Dental And Spine Units Of Zimmer Biomet

ZimVie Inc. to Report Q1, 2022 Results on May 05, 2022

Forecast to breakeven in 2022

ZimVie Inc. Provides Revenue Guidance for the Year Ending December 31, 2022

High number of new and inexperienced directors

ZimVie Inc.(NasdaqGS:ZIMV) dropped from S&P 500 Health Care (Sector)

ZimVie Inc.(NasdaqGS:ZIMV) dropped from S&P Global 1200

ZimVie Inc. Announces Board of Directors

결제의 안정성과 성장

시장 대비 배당 수익률

주주에 대한 수익 배당금

주주에 대한 현금 배당금

강력한 배당금 지급 기업 알아보기